Latest News & Updates
2025 Conference Recap Now Available
View NowElevate your Hatch-Waxman Strategy for 2026
Join the nation’s most respected forum for pharmaceutical patent litigation as we return to New York for the 22nd Annual Paragraph IV Disputes Conference. This is the must-attend event where brand and generic stakeholders converge to shape litigation strategies, navigate regulatory shifts, and connect with the judiciary.
Don’t miss your chance to join the conversation that’s shaping the future of Hatch-Waxman litigation and:
- Benchmark with top ANDA litigators, in-house counsel, and regulators
- Stay ahead of landmark case developments and evolving PTAB practices
- Network with the leading minds in pharmaceutical IP law
ACI’s Hatch-Waxman Series Advisory Board
Comprised of senior in-house IP counsel from top brand and generic pharma companies, the Advisory Board guides ACI on key litigation trends and emerging issues to ensure leading-edge content and expert faculty.
3,700+
Attendees
560+
Speakers
110+
Sponsors
Who Should Attend
Patent attorneys and litigators (in-house & law firms) who represent:
- Brand name pharmaceutical companies
- Generic pharmaceutical companies
- Biopharmaceutical companies
Earn CLE/Ethics Credits
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.
Learn moreSponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: [email protected]
